ACTO Welcomes Former J&J President Lori Tierney to Its Board of Directors
In a significant move for the life sciences sector, ACTO, a leading provider of AI-driven Intelligent Field Excellence (IFE) solutions, has appointed Lori Tierney, the former president of Johnson & Johnson Vision, to its Board of Directors. This strategic appointment comes at a pivotal time as ACTO aims to push the boundaries of customer engagement through innovative artificial intelligence technologies.
Lori Tierney brings over 20 years of extensive experience in the life sciences industry, particularly in commercializing transformative therapies. Having held various high-impact leadership roles within global and regional functions at Johnson & Johnson MedTech and Mentor Aesthetics Specialty Surgery, her expertise is likely to bolster ACTO's mission. Tierney has also held prominent positions at AstraZeneca, Endo Pharmaceuticals, and Centocor, where she successfully led large-scale marketing and sales teams on both global and strategic levels.
Her rich background in overseeing business operations that support over 10,000 customer-oriented professionals positions Tierney as a crucial asset for ACTO. Her commitment to customer-centric innovation in life sciences complements the company's vision to pioneer an AI-driven future in this dynamic industry.
"I have had the privilege of working across all facets of commercial strategy, from brand launches to building field teams and enhancing market access," said Tierney. "The way our sector interacts with healthcare professionals, patients, and payers is undergoing a radical transformation. AI is no longer a luxury; it is essential. ACTO is uniquely positioned to lead this transformation, and I am honored to support its mission to empower individuals and organizations with critical medical insights that drive healthcare progress and improve patient outcomes."
ACTO's Intelligent Field Excellence platform equips life sciences companies with AI-based tools that enable field representatives to engage with customers confidently, credibly, and competently. This platform not only enhances the interactions between field representatives and healthcare professionals but also provides real-time insights to senior leaders, enabling smarter decision-making and continuous commercial execution improvement.
As the life sciences sector faces increasing pressure to boost both revenue growth and operational efficiency, the urgency for AI-driven strategies has never been greater. "We are thrilled to welcome Lori to our Board," explained Parth Khanna, ACTO's CEO. "She brings invaluable industry insights, vast experience, and a bold vision that will be fundamental as we drive towards an AI-centric future in life sciences. Lori embodies the values and ambition that define ACTO, and her guidance will accelerate the evolution of AI in the industry."
For more insights about ACTO and its latest news, visit www.acto.com or follow ACTO on LinkedIn. ACTO is dedicated to enhancing customer engagement and brand performance by transforming field professionals into 'Message Masters' who engage healthcare providers with authority and impact. This platform, validated under FDA 21 CFR Part 11 and certified SOC 2 Type II, stands as a trusted partner for intelligent field excellence in the life sciences industry.
This recent development represents a forward-thinking approach not only for ACTO but for the industry at large, as it showcases a commitment to embracing the future of healthcare through technological advancements in artificial intelligence. As ACTO continues to innovate and expand its reach, Tierney's leadership is expected to play a pivotal role in shaping the company's future and the overall landscape of the life sciences sector.
Lori Tierney brings over 20 years of extensive experience in the life sciences industry, particularly in commercializing transformative therapies. Having held various high-impact leadership roles within global and regional functions at Johnson & Johnson MedTech and Mentor Aesthetics Specialty Surgery, her expertise is likely to bolster ACTO's mission. Tierney has also held prominent positions at AstraZeneca, Endo Pharmaceuticals, and Centocor, where she successfully led large-scale marketing and sales teams on both global and strategic levels.
Her rich background in overseeing business operations that support over 10,000 customer-oriented professionals positions Tierney as a crucial asset for ACTO. Her commitment to customer-centric innovation in life sciences complements the company's vision to pioneer an AI-driven future in this dynamic industry.
"I have had the privilege of working across all facets of commercial strategy, from brand launches to building field teams and enhancing market access," said Tierney. "The way our sector interacts with healthcare professionals, patients, and payers is undergoing a radical transformation. AI is no longer a luxury; it is essential. ACTO is uniquely positioned to lead this transformation, and I am honored to support its mission to empower individuals and organizations with critical medical insights that drive healthcare progress and improve patient outcomes."
ACTO's Intelligent Field Excellence platform equips life sciences companies with AI-based tools that enable field representatives to engage with customers confidently, credibly, and competently. This platform not only enhances the interactions between field representatives and healthcare professionals but also provides real-time insights to senior leaders, enabling smarter decision-making and continuous commercial execution improvement.
As the life sciences sector faces increasing pressure to boost both revenue growth and operational efficiency, the urgency for AI-driven strategies has never been greater. "We are thrilled to welcome Lori to our Board," explained Parth Khanna, ACTO's CEO. "She brings invaluable industry insights, vast experience, and a bold vision that will be fundamental as we drive towards an AI-centric future in life sciences. Lori embodies the values and ambition that define ACTO, and her guidance will accelerate the evolution of AI in the industry."
For more insights about ACTO and its latest news, visit www.acto.com or follow ACTO on LinkedIn. ACTO is dedicated to enhancing customer engagement and brand performance by transforming field professionals into 'Message Masters' who engage healthcare providers with authority and impact. This platform, validated under FDA 21 CFR Part 11 and certified SOC 2 Type II, stands as a trusted partner for intelligent field excellence in the life sciences industry.
This recent development represents a forward-thinking approach not only for ACTO but for the industry at large, as it showcases a commitment to embracing the future of healthcare through technological advancements in artificial intelligence. As ACTO continues to innovate and expand its reach, Tierney's leadership is expected to play a pivotal role in shaping the company's future and the overall landscape of the life sciences sector.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.